Yang, T., Lin, Q., Ren, J., Chen, P., Yuan, X., Luo, X., . . . Hu, J. (2016). A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies. Oncotarget.
Chicago-стиль цитированияYang, Ting, et al. "A 5-day Cytoreductive Chemotherapy Followed By Haplo-identical Hsct (FA5-BUCY) As a Tumor-ablative Regimen Improved the Survival of Patients With Advanced Hematological Malignancies." Oncotarget 2016.
MLA-цитированиеYang, Ting, et al. "A 5-day Cytoreductive Chemotherapy Followed By Haplo-identical Hsct (FA5-BUCY) As a Tumor-ablative Regimen Improved the Survival of Patients With Advanced Hematological Malignancies." Oncotarget 2016.